Author: United States. Congress. House. Committee on Government Operations. Intergovernmental Relations and Human Resources SubcommitteePublisher:
ISBN:
Category : Analgesics
Languages : en
Pages : 568
Book Description
FDA's Regulation of Zomax
Author: United States. Congress. House. Committee on Government Operations. Intergovernmental Relations and Human Resources SubcommitteePublisher:
ISBN:
Category : Analgesics
Languages : en
Pages : 568
Book Description
FDA'S REGULATION OF ZOMAX: HEARINGS before a Subcommittee on Government Operations House of Representatives, 98th Congress.
Author: Monthly Catalogue, United States Public Documents
Author: Publisher:
ISBN:
Category : Government publications
Languages : en
Pages : 1252
Book Description
Monthly Catalog of United States Government Publications
Author: United States Congressional Serial Set Catalog
Author: Publisher:
ISBN:
Category : Government publications
Languages : en
Pages : 834
Book Description
FDA's Regulation of the New Drug Suprol
Author: United States. Congress. House. Committee on Government Operations. Human Resources and Intergovernmental Relations SubcommitteePublisher:
ISBN:
Category : Drugs
Languages : en
Pages : 456
Book Description
Current Catalog
Author: National Library of Medicine (U.S.)Publisher:
ISBN:
Category : Medicine
Languages : en
Pages : 1956
Book Description
National Library of Medicine Current Catalog
Author: National Library of Medicine (U.S.)Publisher:
ISBN:
Category : Medicine
Languages : en
Pages : 988
Book Description
The Fifth Branch
Author: Sheila JasanoffPublisher: Harvard University Press
ISBN: 9780674039117
Category : Political Science
Languages : en
Pages : 322
Book Description
How can decisionmakers charged with protecting the environment and the public's health and safety steer clear of false and misleading scientific research? Is it possible to give scientists a stronger voice in regulatory processes without yielding too much control over policy, and how can this be harmonized with democratic values? These are just some of the many controversial and timely questions that Sheila Jasanoff asks in this study of the way science advisers shape federal policy. In their expanding role as advisers, scientists have emerged as a formidable fifth branch of government. But even though the growing dependence of regulatory agencies on scientific and technical information has granted scientists a greater influence on public policy, opinions differ as to how those contributions should be balanced against other policy concerns. More important, who should define what counts as good science when all scientific claims incorporate social factors and are subject to negotiation? Jasanoff begins by describing some significant failures--such as nitrites, Love Canal, and alar--in administrative and judicial decisionmaking that fed the demand for more peer review of regulatory science. In analyzing the nature of scientific claims and methods used in policy decisions, she draws comparisons with the promises and limitations of peer review in scientific organizations operating outside the regulatory context. The discussion of advisory mechanisms draws on the author's close scrutiny of two highly visible federal agencies--the Environmental Protection Agency and the Food and Drug Administration. Here we see the experts in action as they deliberate on critical issues such as clean air, pesticide regulation, and the safety of pharmaceuticals and food additives. Jasanoff deftly merges legal and institutional analysis with social studies of science and presents a strong case for procedural reforms. In so doing, she articulates a social-construction model that is intended to buttress the effectiveness of the fifth branch.
Granting Additional Market Exclusivity to the Drug Ansaid
Author: United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the EnvironmentPublisher:
ISBN:
Category : Business & Economics
Languages : en
Pages : 72
Book Description